Erlotinib, a highly specific tyrosine kinase inhibitor that can reversibly inhibit epidermal growth factor receptor mutations, is mainly used for targeted therapy following the failure of chemotherapy for non-small-cell lung cancer (NSCLC). Here, EGFR is linked to non-small cell lung carcinoma.